中慧生物-B(02627.HK)盘中涨逾9% 重组呼吸道合胞病毒疫苗IND申请获中国及美国批准

Core Viewpoint - Zhonghui Biotech-B (02627.HK) has received approval for its self-developed recombinant respiratory syncytial virus vaccine from both the National Medical Products Administration (NMPA) in China and the U.S. Food and Drug Administration (FDA) [1] Group 1 - The company's stock price increased by over 9% shortly after market opening, currently up by 6.3%, trading at HKD 50.15 [1] - The vaccine is developed using CHO cell technology and is in the clinical trial phase [1] - The approval from the NMPA and FDA marks a significant milestone for the company in its vaccine development efforts [1]